Utah Medical Products Inc

UTMD’s price has dipped below the 9EMA, 20EMA, and 50DMA with an active Lower Highs & Lower Lows pattern indicating supply dominance and downward momentum. In a Stage 4 decline with neutral OB/OS, the medium-term posture remains bearish. Short-term timing conditions align with further downside as price tightly tracks below sloping EMAs. Execution is now appropriate on rallies into the broken EMA cluster. Only a sustained reclaim above these EMAs and recent resistance zone would invalidate this stance.

• ↑Earnings Yield 36.7% and Dividend Yield 1.8% support income investors.
• ↑Q2 revenue fell 14.3% to $8.53M while gross margin stayed 55.8%.
• ↓2026 sales forecast cut 10–13% after customer losses